Addyi Satisfaction Trends Over Time

What the Key Trials Actually Showed

Flibanserin earned FDA approval on the basis of three Phase III randomized controlled trials (VIOLET, DAISY, BEGONIA) enrolling a combined total of approximately 3,500 premenopausal women with generalized acquired HSDD. The drug beat placebo, but the margins were narrow, and interpreting what "modest" means for a given patient requires looking at the numbers directly.

In the BEGONIA trial (N=1,175), women receiving flibanserin 100 mg at bedtime reported a mean increase of approximately 0.5 additional satisfying sexual events (SSEs) per month compared with placebo over 24 weeks [1]. The VIOLET trial (N=1,247) and DAISY trial (N=1,091) produced similar effect sizes [2]. Across all three studies, the co-primary endpoint of desire, measured by the Female Sexual Function Index desire domain, improved by roughly 0.3 to 0.4 points on a 1.2 to 6.0 scale versus placebo [1][2].

The FDA's own briefing document noted that the clinical significance of these effect sizes was debated. Dr. Adriane Fugh-Berman, a Georgetown University pharmacology professor, stated during the 2015 advisory committee meeting: "The drug is marginally effective. If you think about it, half an extra satisfying sexual event per month is difficult to distinguish from placebo in daily life" [3]. Supporters countered that desire is subjective and that even small mean differences can represent large quality-of-life shifts for individual responders.

The number needed to treat (NNT) was estimated at 8 to 10, meaning roughly 1 in 8 to 10 women experienced a clinically meaningful response beyond what placebo provided [3]. That is not unusual for CNS-active drugs, but it does mean the majority of users will not see a clear benefit.

Early Post-Approval Prescribing and the REMS Barrier

When Addyi launched in October 2015, the FDA imposed a Risk Evaluation and Mitigation Strategy (REMS) that required prescribers to complete certification training and pharmacies to become specially certified before dispensing the drug. Patients had to sign a form acknowledging the risk of severe hypotension and syncope when combining flibanserin with alcohol [4].

These restrictions suppressed uptake dramatically. Sprout Pharmaceuticals reported only about 4,000 prescriptions filled in the first four months after launch [5]. For comparison, sildenafil generated over 300,000 prescriptions in its first month in 1998. The gap is not entirely attributable to the REMS (HSDD awareness, stigma, and insurance coverage all played roles), but the certification process deterred many gynecologists and primary care physicians from prescribing.

In 2019, the FDA removed the REMS requirement after reviewing post-market safety data showing the alcohol interaction risk was lower than initially estimated [4]. The label retained a contraindication for concomitant use with moderate or strong CYP3A4 inhibitors and a warning about alcohol, but the prescriber certification barrier was eliminated.

Prescription volume increased modestly after the REMS removal. The International Society for the Study of Women's Sexual Health (ISSWSH) had advocated for the change, with ISSWSH president Dr. Sheryl Kingsberg noting: "No other drug carries a REMS simply because of an interaction with alcohol. The REMS was a barrier to access that was not applied equitably compared to medications for male sexual dysfunction" [6].

What Patient Forums and Review Platforms Reveal

Online patient reviews of Addyi are genuinely split. This is consistent with the clinical trial data showing a moderate-sized responder subgroup alongside a majority of non-responders.

On Drugs.com, flibanserin carries an average rating of approximately 5.5 out of 10 based on user-submitted reviews (as of early 2026). The distribution is bimodal: ratings cluster at 1 to 3 (dissatisfied) and 8 to 10 (very satisfied), with fewer reviews in the middle range [7]. This pattern is common for drugs where individual response variation is high.

Satisfied users frequently describe a gradual onset. A recurring theme on Reddit's r/HSDD and r/WomensHealth forums is that benefit appeared after 6 to 10 weeks, not immediately. Users who quit before 8 weeks often reported no effect, which aligns with prescribing guidance recommending discontinuation only after 8 weeks of no improvement [4].

Dissatisfied reviewers cite two main complaints: side effects (particularly daytime drowsiness and dizziness) and underwhelming efficacy. Several Reddit threads describe the experience as "not worth the side effects for such a small change." Selection bias is a significant caveat here. Patients who feel strongly (positive or negative) are overrepresented on review platforms. The large middle group of women who experienced mild or ambiguous benefit and quietly discontinued rarely post.

A separate concern raised in online communities is cost. Without insurance coverage, Addyi's retail price has ranged from $400 to over $800 per month. Generic flibanserin became available after patent expiry, bringing cash-pay prices closer to $30 to $80 per month through discount pharmacy programs, which has shifted the cost-benefit calculation for many patients.

Discontinuation Rates and What They Signal

High discontinuation is the clearest real-world signal about Addyi satisfaction. Across multiple observational analyses, more than half of women who filled an initial prescription did not continue past 6 to 12 months [8].

A 2020 retrospective claims analysis published in the Journal of Women's Health examined commercial insurance data and found that only 29% of women who initiated flibanserin were still filling prescriptions at 12 months [8]. The most common reasons for discontinuation in clinical practice, according to survey data, were inadequate efficacy (cited by approximately 40% of discontinuers) and side effects (cited by approximately 25%) [8].

These numbers are not unique to flibanserin. Antidepressants, which share some pharmacological overlap as CNS serotonergic agents, also show 12-month persistence rates in the range of 40 to 60% [9]. The comparison matters because it contextualizes Addyi's dropout rate within a class of drugs that requires weeks to reach full effect and that produces variable individual responses.

For women who do persist, the data suggest continued or improving benefit. The open-label extension of the BEGONIA trial followed responders for up to 52 weeks and found that SSE counts remained stable or continued to improve modestly, with no new safety signals [1][10]. This supports the clinical recommendation to continue treatment if benefit is established by week 8 to 12.

How Addyi Compares to Bremelanotide (Vyleesi) in User Perception

Bremelanotide (Vyleesi), approved in June 2019 as the second FDA-approved treatment for premenopausal HSDD, offers an on-demand alternative to Addyi's daily dosing [11]. The two drugs target different receptor systems (bremelanotide activates melanocortin-4 receptors), and head-to-head trial data do not exist, but patient forums frequently compare them.

In the RECONNECT trials (N=1,247 combined), bremelanotide 1.75 mg subcutaneous injection increased desire scores by approximately 0.35 points on the FSFI desire domain versus placebo and increased SSEs modestly [11]. The effect sizes are broadly similar to flibanserin's.

The patient experience differs substantially. Bremelanotide is injected subcutaneously via an autoinjector at least 45 minutes before anticipated sexual activity. Nausea occurs in roughly 40% of users (typically resolving with repeated use), and about 18% of participants in RECONNECT discontinued due to adverse events [11]. Online reviews on Drugs.com give bremelanotide a similar average rating to flibanserin (approximately 5.0 to 5.5 out of 10), with the same bimodal distribution.

Forum discussions often frame the choice as daily-but-oral (Addyi) versus as-needed-but-injectable (Vyleesi). Women who dislike daily medication or who experience next-day drowsiness with flibanserin tend to prefer bremelanotide. Women who dislike injections or who experience severe nausea with bremelanotide tend to prefer flibanserin. Neither drug has emerged as a clear patient-satisfaction winner.

Factors That Predict a Better Response

Not every woman with HSDD is equally likely to benefit from flibanserin. Subgroup analyses from the key trials and post-market data identify several variables associated with higher response rates.

Severity of baseline desire impairment matters. Women with lower baseline FSFI desire domain scores (indicating more severe hypoactive desire) showed larger absolute improvements with flibanserin than women with milder deficits [1][2]. This ceiling-effect pattern is typical in CNS pharmacology.

Concurrent SSRI or SNRI use complicates the picture. The key trials excluded women taking serotonergic antidepressants because flibanserin's mechanism involves serotonin receptor modulation [1]. In clinical practice, many women with HSDD also take antidepressants (which can themselves cause sexual dysfunction), creating a population for whom flibanserin's efficacy is not well characterized. The ISSWSH process of care algorithm recommends addressing medication-induced sexual dysfunction before initiating flibanserin [12].

Relationship context also influences outcomes. The key trials required participants to be in stable, monogamous relationships, so the generalizability to other relationship structures is uncertain [1]. Psychosocial contributors to low desire (relationship dissatisfaction, history of trauma, chronic stress) may attenuate pharmacological benefit and are best addressed concurrently through counseling or sex therapy, as recommended by the ISSWSH clinical guidelines [12].

Alcohol use patterns remain relevant despite the REMS removal. The original interaction studies showed that combining flibanserin with alcohol increased the risk of clinically significant hypotension. The current label advises patients to discontinue alcohol at least 2 hours before taking the nightly dose, though the absolute risk for moderate drinkers appears lower than early safety studies suggested [4].

The Satisfaction Trajectory: What to Expect Week by Week

For clinicians counseling patients and for women considering Addyi, a realistic timeline helps set expectations and reduces premature discontinuation.

Weeks 1 to 4 represent the adjustment phase. Side effects (dizziness, somnolence, nausea) are most pronounced during this period. Most women who will experience side effects notice them in the first 2 weeks. Taking the dose at bedtime and ensuring at least 7 hours before needing to drive or operate machinery mitigates daytime sedation [4].

Weeks 4 to 8 are the early efficacy window. Some women notice subtle shifts in receptivity, spontaneous sexual thoughts, or interest in initiation. The effect is not comparable to a phosphodiesterase-5 inhibitor's acute, event-specific action. It is more accurately described as a gradual upward drift in baseline desire.

Week 8 is the decision point. The FDA label and clinical guidelines recommend that women who have not experienced meaningful improvement by 8 weeks discontinue the medication [4]. Continuing beyond this point in non-responders exposes them to ongoing side-effect risk without expected benefit.

Weeks 8 to 24 and beyond represent the maintenance phase for responders. Open-label extension data from the key program showed that SSE improvements were maintained through 52 weeks of continuous treatment, with a slight trend toward further improvement between months 3 and 6 [10]. Women who discontinue after responding should expect desire to return to baseline, as flibanserin does not produce lasting neuroadaptive changes after cessation.

Putting the Numbers in Clinical Context

Flibanserin's trial-level efficacy is modest by any standard metric. Half an additional satisfying sexual event per month is the number most frequently cited by both proponents and critics. But averages can obscure the responder distribution.

A post-hoc responder analysis of the pooled key trial data found that approximately 10 to 12% more women in the flibanserin group achieved a clinically meaningful increase in SSEs (defined as 2 or more additional events per month) compared with placebo [2][10]. For those responders, the benefit was not trivial. The mean improvement among responders was approximately 2.5 additional SSEs per month, which represents a qualitatively different sexual life for someone who previously experienced near-zero desire [10].

The American College of Obstetricians and Gynecologists (ACOG) has stated that flibanserin "may be considered" for premenopausal women with acquired, generalized HSDD after non-pharmacologic interventions have been attempted [13]. This tepid endorsement reflects the evidence base: the drug works for a subset of patients, the effect for that subset can be meaningful, but identifying responders prospectively remains difficult.

Prescribers who set expectations clearly, emphasize the 8-week evaluation timeline, and address concurrent psychosocial or pharmacological contributors to low desire give their patients the best chance of a satisfactory outcome. Women who reach week 8 and notice improved desire or sexual satisfaction should continue. Those who do not should stop, re-evaluate contributing factors, and consider bremelanotide or off-label alternatives such as testosterone (used off-label in women per the Global Consensus Position Statement on testosterone therapy for women) [14].